Initiated Overweight X

PRCT PROCEPT BioRobotics

Morgan Stanley

$105

Initiated Hold X

PRCT PROCEPT BioRobotics

Jefferies

$95

Initiated Overweight X

PRCT PROCEPT BioRobotics

Piper Sandler

$42

Initiated Outperform X

PRCT PROCEPT BioRobotics

William Blair

Initiated Neutral X

PRCT PROCEPT BioRobotics

BTIG Research

Initiated Buy X

PRCT PROCEPT BioRobotics

Truist

$58

Initiated Overweight X

PRCT PROCEPT BioRobotics

Wells Fargo

$49

Initiated Overweight X

PRCT PROCEPT BioRobotics

KeyBanc Capital Markets

$47

Initiated Buy X

PRCT PROCEPT BioRobotics

B. Riley Securities

$53

PRCT  PROCEPT BioRobotics Corporation

PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. As of December 31, 2021, it had an install base of 130 AquaBeam Robotic Systems worldwide comprising 78 in the United States. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.